Amgen (AMGN) VP Matthew Busch granted RSUs and options, small tax share withholding
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Amgen executive Matthew C. Busch, VP Finance & CAO, reported routine equity compensation grants and related tax withholding. He received 455 shares of common stock as Restricted Stock Units, including 45 Dividend Equivalents, under Amgen’s Equity Incentive Plan. These RSUs vest in four equal 25% installments starting on 5/5/2027 and are settled in common shares.
Busch also received 2,969 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from 5/5/2027 until expiration on 5/5/2036. To cover tax obligations, 50 shares of common stock were disposed of at $329.59 per share as a tax-withholding transaction, not an open-market sale. After these transactions, he directly holds 4,385 common shares.
Positive
- None.
Negative
- None.
Insights
Routine Amgen executive equity grants with small tax withholding.
The filing shows Matthew C. Busch, Amgen’s VP Finance & CAO, receiving standard long-term incentives: 455 RSU-based shares (including Dividend Equivalents) and 2,969 non-qualified stock options, all vesting in four annual installments beginning on 5/5/2027.
The 50-share disposition at $329.59 per share is a tax-withholding event rather than an open-market sale, so it carries little informational signal about sentiment. Following these transactions, Busch directly holds 4,385 shares, indicating the activity is modest relative to his overall equity position.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Busch Matthew C.
Role
VP, Finance & CAO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 50 | $329.59 | $16K |
| Grant/Award | Nqso (Right to Buy) | 2,969 | $329.59 | $979K |
| Grant/Award | Common Stock | 455 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 4,385 shares (Direct, null);
Nqso (Right to Buy) — 2,969 shares (Direct, null)
Footnotes (1)
- The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.
Key Figures
RSU shares granted: 455 shares
Dividend Equivalents included: 45 shares
Options granted: 2,969 options
+4 more
7 metrics
RSU shares granted
455 shares
Restricted Stock Units granted, including 45 Dividend Equivalents, vesting from May 5, 2027
Dividend Equivalents included
45 shares
Dividend Equivalents credited to unvested RSUs under Equity Incentive Plan
Options granted
2,969 options
Non-qualified stock options to buy Amgen common stock
Option exercise price
$329.59 per share
Conversion or exercise price of non-qualified stock options
Option expiration date
May 5, 2036
Expiration date of non-qualified stock options if unexercised
Tax-withheld shares
50 shares
Shares disposed of to satisfy tax liability at $329.59 per share
Shares after transactions
4,385 shares
Direct Amgen common stock holdings following reported Form 4 transactions
Key Terms
Restricted Stock Units (RSUs), Dividend Equivalents (DEs), non-qualified stock options, Equity Incentive Plan, +1 more
5 terms
Restricted Stock Units (RSUs) financial
"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Dividend Equivalents (DEs) financial
"These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan"
non-qualified stock options financial
"These non-qualified stock options were granted pursuant to the Equity Incentive Plan"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
Equity Incentive Plan financial
"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan)"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
FAQ
What did Amgen (AMGN) executive Matthew C. Busch receive in this Form 4 filing?
Matthew C. Busch received 455 shares of Amgen common stock as Restricted Stock Units and 2,969 non-qualified stock options. Both awards were granted under Amgen’s Equity Incentive Plan and are structured to vest gradually over four years starting on May 5, 2027.
How do the new Amgen (AMGN) RSUs for Matthew C. Busch vest?
The 455 Restricted Stock Units for Matthew C. Busch vest in four equal 25% installments beginning May 5, 2027. Upon vesting, each RSU converts into one share of Amgen common stock, providing a staggered equity delivery schedule that aligns with multi-year retention incentives.
What are the terms of Matthew C. Busch’s new Amgen (AMGN) stock options?
Busch was granted 2,969 non-qualified stock options with a $329.59 exercise price. These options vest and become exercisable in four equal annual 25% installments starting May 5, 2027, and remain exercisable until their expiration on May 5, 2036, if vested.
What are Dividend Equivalents (DEs) mentioned in the Amgen (AMGN) Form 4?
Dividend Equivalents are credits tied to unvested RSUs that mirror dividends on Amgen shares. Busch’s 455 RSUs include 45 DEs, which are added to his RSUs and paid out in Amgen common stock on a one-to-one basis following the same vesting schedule, plus cash for any fractional share amount.